Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEN NASDAQ:NVCT NASDAQ:OKUR NASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$3.03+6.3%$2.48$1.29▼$3.23$269.48M2.79503,705 shs772,841 shsNVCTNuvectis Pharma$12.45+3.4%$8.84$5.55▼$13.34$319.37M-0.1182,750 shs169,361 shsOKUROnKure Therapeutics$3.34-1.8%$4.17$1.77▼$5.38$137.35M0.36134,523 shs90,200 shsREPLReplimune Group$4.93-7.0%$5.38$1.50▼$13.24$437.64M0.128.34 million shs9.27 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen+6.32%+5.94%+5.21%+83.64%+131.30%NVCTNuvectis Pharma+3.41%+20.64%+42.61%+42.12%+34.74%OKUROnKure Therapeutics-1.76%-15.66%-27.55%+38.02%+82.51%REPLReplimune Group-6.98%+47.60%+152.82%-38.14%-29.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$3.03+6.3%$2.48$1.29▼$3.23$269.48M2.79503,705 shs772,841 shsNVCTNuvectis Pharma$12.45+3.4%$8.84$5.55▼$13.34$319.37M-0.1182,750 shs169,361 shsOKUROnKure Therapeutics$3.34-1.8%$4.17$1.77▼$5.38$137.35M0.36134,523 shs90,200 shsREPLReplimune Group$4.93-7.0%$5.38$1.50▼$13.24$437.64M0.128.34 million shs9.27 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen+6.32%+5.94%+5.21%+83.64%+131.30%NVCTNuvectis Pharma+3.41%+20.64%+42.61%+42.12%+34.74%OKUROnKure Therapeutics-1.76%-15.66%-27.55%+38.02%+82.51%REPLReplimune Group-6.98%+47.60%+152.82%-38.14%-29.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 2.75Moderate Buy$5.0065.02% UpsideNVCTNuvectis Pharma 2.00Hold$10.00-19.68% DownsideOKUROnKure Therapeutics 2.00Hold$27.00708.38% UpsideREPLReplimune Group 1.60Reduce$4.75-3.65% DownsideCurrent Analyst Ratings BreakdownLatest OKUR, REPL, CGEN, and NVCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026OKUROnKure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/8/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/7/2026OKUROnKure Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/24/2026OKUROnKure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026CGENCompugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026REPLReplimune Group Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Hold4/13/2026REPLReplimune Group BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform4/13/2026REPLReplimune Group Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$11.00 ➝ $2.004/13/2026REPLReplimune Group Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$13.00 ➝ $2.004/13/2026REPLReplimune Group WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$19.00 ➝ $2.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$72.76M3.94$0.40 per share7.63$1.09 per share2.78NVCTNuvectis PharmaN/AN/AN/AN/A$0.54 per shareN/AOKUROnKure TherapeuticsN/AN/AN/AN/A$4.56 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen$35.34M$0.378.19N/AN/A48.57%55.68%29.68%5/18/2026 (Estimated)NVCTNuvectis Pharma-$26.44M-$1.31N/AN/AN/AN/A-161.00%-98.88%N/AOKUROnKure Therapeutics-$59.52M-$4.33N/AN/AN/AN/A-61.02%-55.99%N/AREPLReplimune Group-$247.30M-$3.44N/AN/AN/AN/A-102.69%-72.22%5/28/2026 (Estimated)Latest OKUR, REPL, CGEN, and NVCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2026Q4 2026REPLReplimune Group-$0.73N/AN/AN/A$0.95 millionN/A5/18/2026Q1 2026CGENCompugen-$0.07N/AN/AN/A$1.57 millionN/A5/5/2026Q1 2026NVCTNuvectis Pharma-$0.30-$0.26+$0.04-$0.26N/AN/A5/5/2026Q1 2026OKUROnKure Therapeutics-$0.7425-$1.11-$0.3675-$1.11$0.17 millionN/A3/12/2026Q4 2025OKUROnKure Therapeutics-$1.15-$0.99+$0.16-$0.99N/AN/A3/2/2026Q4 2025CGENCompugen$0.05$0.60+$0.55$0.60$14.30 million$67.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A6.566.56NVCTNuvectis PharmaN/A2.272.27OKUROnKure TherapeuticsN/A13.7813.78REPLReplimune Group0.335.605.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%NVCTNuvectis Pharma96.77%OKUROnKure Therapeutics90.98%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipCGENCompugen9.50%NVCTNuvectis Pharma30.52%OKUROnKure Therapeutics2.30%REPLReplimune Group5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7094.55 million85.57 millionOptionableNVCTNuvectis Pharma826.53 million18.43 millionNot OptionableOKUROnKure TherapeuticsN/A40.40 million13.36 millionN/AREPLReplimune Group21082.57 million78.28 millionOptionableOKUR, REPL, CGEN, and NVCT HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPLMay 14 at 8:15 PM | prnewswire.comReplimune: Perhaps The FDA Shakeup Will Get A Mulligan For RP1May 13 at 11:44 PM | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPLMay 12 at 5:24 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPLMay 7, 2026 | prnewswire.comInconsistency From the FDA Has Become a Huge TaxMay 7, 2026 | realclearmarkets.comRFDA's Makary defends Replimune drug rejection amid backlashMay 5, 2026 | msn.comFDA Commissioner Makary defends agency's decision on Replimune's drug, CNBC reportsMay 5, 2026 | msn.comWhat's going on with Replimune stock on Tuesday?May 5, 2026 | msn.comShort Interest in Replimune Group, Inc. (NASDAQ:REPL) Grows By 12.8%May 1, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPLApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune ...April 29, 2026 | bakersfield.comBReplimune Group (REPL) price target decreased by 59.94% to 5.04April 29, 2026 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPLApril 28, 2026 | globenewswire.comReplimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingApril 27, 2026 | finance.yahoo.com200+ Mass. biotech employees were laid off last week. That may only be the beginningApril 25, 2026 | masslive.comMReplimune Group (NASDAQ:REPL) Cut to "Strong Sell" at Wall Street ZenApril 25, 2026 | marketbeat.comUS Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejectionApril 22, 2026 | reuters.comInvestors Purchase Large Volume of Replimune Group Call Options (NASDAQ:REPL)April 22, 2026 | marketbeat.comReplimune escalates layoffs to cut 224 Massachusetts jobsApril 21, 2026 | bizjournals.comReplimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Reduce" from BrokeragesApril 21, 2026 | marketbeat.comJefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA DecisionApril 17, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026NVIDIA's Quantum Computing Play Just Sent IonQ and Rigetti Flying By Jeffrey Neal Johnson | April 15, 2026Bitcoin and Big Tech Rally as Risk Appetite Returns, Even With Ceasefire UncertaintyBy Jessica Mitacek | April 21, 2026The PDT Rule Is On Its Way Out: 5 Stocks That Stand to Benefit the MostBy Ryan Hasson | April 20, 2026OKUR, REPL, CGEN, and NVCT Company DescriptionsCompugen NASDAQ:CGEN$3.03 +0.18 (+6.32%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$2.96 -0.07 (-2.31%) As of 04:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Nuvectis Pharma NASDAQ:NVCT$12.45 +0.41 (+3.41%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$11.66 -0.80 (-6.39%) As of 05/14/2026 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.OnKure Therapeutics NASDAQ:OKUR$3.34 -0.06 (-1.76%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$3.34 0.00 (-0.15%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.Replimune Group NASDAQ:REPL$4.93 -0.37 (-6.98%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$4.96 +0.03 (+0.51%) As of 04:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
